Exploring the Emerging Treatment Landscape of Relapsed/Refractory Diffuse Large B-Cell Lymphoma: A Focus on Novel Immunotherapies

This activity was originally presented at the 2022 ASHP Midyear Clinical Meeting & Exposition.

Program Description

Diffuse large B-cell lymphoma (DLBCL) accounts for 25% to 45% of new lymphoma cases each year and is the most common aggressive subtype of non-Hodgkin lymphoma. The standard of care has been treatment with an anti-CD20 antibody along with cyclophosphamide, doxorubicin, prednisone, and vincristine (R-CHOP). Despite treatment with chemotherapy and autologous stem-cell transplantation, up to 30% and 40% of patients experience disease relapse. Outcomes are likely to be improved with newer strategies such as chimeric antigen receptor T-cell therapies, antibody-drug conjugates, and bispecific antibodies. As new therapies and combinations emerge, it is important for pharmacists to remain up to date on emerging data while being familiar with guideline recommendations to individualize treatment and provide the best possible care to patients. Following an overview of the current landscape of DLBCL treatment and management, audience members will be able to choose topics for an expert panel discussion based on challenges they experience in practice. Panelists will discuss the pharmacology and clinical data supporting use of new treatment options for DLBCL and share considerations for incorporating these new therapies and guideline recommendations into clinical practice.

Target audience: Health System and Oncology Pharmacists

Type of activity: Application
Release date: December 22, 2022
Expiration date: December 22, 2023

Time to complete activity: 1.5 hours
Fee: Free

Educational Objectives

At the completion of this activity, participants will be able to:

• Examine pharmacologic properties of novel immunotherapies for the treatment of relapsed/refractory diffuse large B-cell lymphoma (R/R DLBCL)
• Analyze recent and emerging clinical data investigating novel immunotherapies in the treatment of R/R DLBCL
• Apply guideline recommendations to individualized treatment selection for a patient with R/R DLBCL
• Identify solutions to address challenges and uncertainties with novel immunotherapies for the treatment of R/R DLBCL

Pharmacy Times Continuing Education™ is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a provider of continuing pharmacy education. This activity is approved for 1.5 contact hours (0.15 CEU) under the ACPE universal activity number 0290-0000-22-616-H01-P. The activity is available for CE credit through December 22, 2023.

Instructions for Completing the Activity and Receiving CPE Credit

To receive CPE credit, participants must complete the pretest, review the activity in its entirety, complete the posttest, and complete the online activity evaluation. After successful completion of the online activity evaluation, you can submit your credit to CPE Monitor. You may view your credit within 48 hours at www.mycpemonitor.net. All participants must request credit before the activity expiration date. CE credit will not be issued after this date.

Disclosures

Javier Munoz, MD, MS, MBA, FACP, has the following relevant financial relationships with commercial interests to disclose:​

• Grant/Research Support: Bayer, Gilead/Kite Pharma, Celgene, Merck, Portola, Incyte, Genentech, Pharmacyclics, SeaGen, Janssen, Millennium​
• Consultant: Pharmacyclics/AbbVie, Bayer, Gilead/Kite Pharma, Pfizer, Janssen, Juno/Celgene, Bristol Myers Squibb, Kyowa, Alexion, Fosunkite, Innovent, SeaGen, Debiopharm, Karyopharm, Genmab, ADC Therapeutics, Epizyme, BeiGene, Servier, Novartis, Morphosys/Incyte, Mei Pharma, Zodiac​
• Speakers Bureau: Gilead/Kite Pharma, Kyowa, Bayer, Pharmacyclics/Janssen, SeaGen, Acrotech/Aurobindo, BeiGene, Verastem, AstraZeneca, Celgene/Bristol Myers Squibb, Genentech/Roche​
• Honoraria: Targeted Oncology, OncView, Curio, Kyowa, Dava, Global Clinical Insights, Shanghai Youyao, SeaGen

Laura J. Zitella, MS, RN, ACNP-BC, AOCN, has the following financial relationships with commercial interests to disclose:
Speakers Bureau: AbbVie

The following contributors have no relevant financial relationships with commercial interests to disclose:

Faculty

Victoria R. Nachar, PharmD, BCOP

Pharmacy Times Continuing Education™ Planning Staff—Jim Palatine, RPh, MBA; Amy Seung, PharmD, BCOP, FHOPA, CHCP; Evelina Kolychev, PharmD, BCOP; Abigail Dill; Susan Pordon; Brianna Winters; and Chloe Taccetta.

Anonymous peer reviewers were used as part of content validation and conflict resolution. The peer reviewers have no relevant financial relationships with commercial interests to disclose.

Educational Disclaimer
CPE activities are offered solely for educational purposes and do not constitute any form of professional advice or referral. Discussions concerning drugs, dosages, and procedures may reflect the clinical experience of the author(s) or they may be derived from the professional literature or other sources and may suggest uses that are investigational in nature and not approved labeling or indications. Participants are encouraged to refer to primary references or full prescribing information resources.

For questions about this internet CPE activity, please contact:
[email protected]
Privacy Policy and Terms of Use Information:
www.pharmacytimes.org/terms